Barclays PLC Alkermes Plc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Alkermes Plc. stock. As of the latest transaction made, Barclays PLC holds 423,931 shares of ALKS stock, worth $12.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

423,931

Previous 423,931 -0.0%

Holding current value

$12.6 Million

Previous $11.9 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$23.01 - $28.55 $5.08 Million - $6.31 Million	220,893 Added 108.79%	423,931 $11.9 Million
Q2 2024 Aug 14, 2024	SELL	$23.21 - $27.24 $736,267 - $864,107	-31,722 Reduced 13.51%	203,038 $4.89 Million
Q1 2024 May 15, 2024	SELL	$26.4 - $32.56 $5.11 Million - $6.3 Million	-193,509 Reduced 45.18%	234,760 $6.36 Million
Q4 2023 Feb 15, 2024	BUY	$23.37 - $28.68 $4.67 Million - $5.73 Million	199,881 Added 87.52%	428,269 $11.9 Million
Q3 2023 Nov 07, 2023	BUY	$27.17 - $31.97 $638,793 - $751,646	23,511 Added 11.48%	228,388 $6.4 Million
Q2 2023 Aug 03, 2023	SELL	$28.34 - $33.63 $2.14 Million - $2.54 Million	-75,516 Reduced 26.93%	204,877 $6.41 Million
Q1 2023 May 04, 2023	SELL	$25.31 - $29.02 $946,416 - $1.09 Million	-37,393 Reduced 11.77%	280,393 $7.91 Million
Q4 2022 Feb 13, 2023	BUY	$21.94 - $26.24 $705,019 - $843,196	32,134 Added 11.25%	317,786 $8.3 Million
Q3 2022 Nov 03, 2022	BUY	$22.0 - $31.87 $5.21 Million - $7.54 Million	236,711 Added 483.67%	285,652 $6.38 Million
Q2 2022 Aug 12, 2022	SELL	$26.4 - $30.54 $141,873 - $164,121	-5,374 Reduced 9.89%	48,941 $1.46 Million
Q1 2022 May 16, 2022	SELL	$23.07 - $27.99 $4.5 Million - $5.46 Million	-194,925 Reduced 78.21%	54,315 $1.43 Million
Q4 2021 Feb 14, 2022	BUY	$21.47 - $32.08 $3.77 Million - $5.64 Million	175,703 Added 238.93%	249,240 $5.8 Million
Q3 2021 Nov 09, 2021	BUY	$23.37 - $32.13 $1.15 Million - $1.58 Million	49,097 Added 200.89%	73,537 $2.27 Million
Q2 2021 Aug 13, 2021	SELL	$18.78 - $25.15 $1.62 Million - $2.16 Million	-86,005 Reduced 77.87%	24,440 $600,000
Q1 2021 May 13, 2021	BUY	$18.21 - $23.2 $1.58 Million - $2.02 Million	86,942 Added 369.92%	110,445 $2.06 Million
Q4 2020 Feb 11, 2021	SELL	$15.39 - $22.1 $71,609 - $102,831	-4,653 Reduced 16.53%	23,503 $468,000
Q3 2020 Nov 12, 2020	SELL	$16.16 - $20.66 $751,440 - $960,690	-46,500 Reduced 62.29%	28,156 $467,000
Q2 2020 Aug 12, 2020	SELL	$13.31 - $19.41 $557,462 - $812,949	-41,883 Reduced 35.94%	74,656 $1.45 Million
Q1 2020 May 13, 2020	SELL	$13.06 - $21.24 $1.29 Million - $2.1 Million	-98,636 Reduced 45.84%	116,539 $1.68 Million
Q4 2019 Feb 10, 2020	SELL	$17.29 - $21.74 $815,448 - $1.03 Million	-47,163 Reduced 17.98%	215,175 $4.39 Million
Q3 2019 Nov 14, 2019	SELL	$19.51 - $24.28 $3.29 Million - $4.09 Million	-168,609 Reduced 39.13%	262,338 $5.12 Million
Q2 2019 Aug 14, 2019	BUY	$21.47 - $37.33 $7.7 Million - $13.4 Million	358,670 Added 496.24%	430,947 $9.71 Million
Q1 2019 May 15, 2019	BUY	$28.4 - $36.49 $617,160 - $792,964	21,731 Added 42.99%	72,277 $2.64 Million
Q4 2018 Feb 14, 2019	SELL	$27.94 - $44.61 $918,695 - $1.47 Million	-32,881 Reduced 39.41%	50,546 $1.49 Million
Q3 2018 Nov 14, 2018	BUY	$38.6 - $46.12 $2.1 Million - $2.51 Million	54,434 Added 187.75%	83,427 $3.54 Million
Q2 2018 Aug 14, 2018	SELL	$40.56 - $51.36 $1.22 Million - $1.54 Million	-30,065 Reduced 50.91%	28,993 $1.19 Million
Q1 2018 May 15, 2018	BUY	$53.61 - $67.26 $1.66 Million - $2.08 Million	30,984 Added 110.37%	59,058 $3.42 Million
Q4 2017 Feb 14, 2018	SELL	$47.69 - $55.39 $173,162 - $201,121	-3,631 Reduced 11.45%	28,074 $1.54 Million
Q3 2017 Nov 14, 2017	BUY	$49.16 - $54.45 $1.56 Million - $1.73 Million	31,705	31,705 $1.61 Million

Others Institutions Holding ALKS

# of Institutions

362

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.87B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account